Ertugliflozin: Phase III started

Pfizer disclosed in its 4Q13 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 5 and 15 mg oral ertugliflozin once daily for 52 weeks in about 450 Type II dia...